(Q54312326)

English

Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.

scientific article published on 31 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

author name string

Gui-Nan Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Jie-Wen Peng

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Pan-Pan Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Dong-Ying Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Jian-Jun Xiao

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Xiao-Qin Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

publication date

31 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Asia Pacific Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

13

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

e189-e194

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Cancer-related inflammation

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Inflammation-based prognostic indices in malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Inflammation and cancer: back to Virchow?

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12273

21 January 2018

Identifiers

10.1111/AJCO.12273

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25359280

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54312326&oldid=833846765"